Navigation Links
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Date:12/18/2007

ike blood vessels in normal tissue, are porous to molecules like polyglutamate. Based on preclinical studies, it appears that XYOTAX is preferentially distributed to tumors due to their leaky blood vessels and trapped in the tumor bed allowing significantly more of the dose of chemotherapy to localize in the tumor than with standard paclitaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy. Preclinical and clinical studies support that XYOTAX metabolism by lung cancer cells may be influenced by estrogen, which could lead to enhanced release of paclitaxel and efficacy in women with lung cancer compared to standard therapies.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of XYOTAX include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with XYOTAX in particular including, without limitation, the potential failure of XYOTAX to prove safe and effective or be approved for treatment of non-small cell lung cancer, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling XYOTAX, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K,
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
3. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
4. Nile Therapeutics, Inc. Adds to Executive Management Team
5. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
6. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
7. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
8. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
9. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
10. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
11. Cell Therapeutics, Inc. (CTI) BIO Presentation to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
(Date:8/21/2014)... , August 21, 2014 ... http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the addition of ...  report to their offering.       ... as hormone therapy, is a means of ... produced by the body. This type of ...
(Date:8/21/2014)... The College of New Rochelle announced ... the Mid-Hudson Region to be designated as a START-UP ... from qualified “high-technology” businesses that align with the College’s ... have been selected for the START-UP NY program and ... stimulate economic development in New York by growing business ...
(Date:8/21/2014)... , Aug. 21, 2014 ... Immune Pharmaceuticals Inc., a biotechnology company, on its ... Immune previously traded on OTCQX®, the best marketplace ... OTC Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... on the successful execution of its growth strategy ...
Breaking Biology Technology:A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 2The College of New Rochelle Becomes First Private College in Mid-Hudson Region to Earn START-UP NY Designation 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2
... KONG, Nov. 1, 2011 OrbusNeich today announced that data from ... of an ablu M inal sirolimus coat ED ... nt), a randomized clinical trial of the Combo Bio-engineered Sirolimus Eluting ... Breaking Clinical Trials and First Report Investigations Session at TCT 2011 ...
... Advanstar|CBI recently announced the full agenda for their ... by 3d Communications. The Forum takes place February 7-8, ... FDA Advisory Committees, speaker faculty includes leading experts from ... Center and many more. Leveraging their ...
... Researchers have used zinc oxide microwires to significantly ... diodes (LED) convert electricity to ultraviolet light. The ... whose performance has been enhanced by the creation ... using the piezo-phototronic effect. By applying mechanical ...
Cached Biology Technology:Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 2Data From REMEDEE Trial Featuring OrbusNeich's Combo™ Dual Therapy Stent to be Presented in Late Breaking Clinical Trials and First Report Investigations Session at TCT 2011 3CBI Announces 3rd Effective Preparation for FDA Advisory Committees 2Zinc oxide microwires improve the performance of light-emitting diodes 2Zinc oxide microwires improve the performance of light-emitting diodes 3
(Date:8/22/2014)... The first comprehensive study of captive black rhino ... improve the success of breeding programmes. , Researchers ... the University of Liverpool carried out a six-year ... black rhino. , Dr Katie Edwards led the ... University of Liverpool. She says: "Although some black ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
(Date:8/22/2014)... and the bees. But that old expression leaves ... fertilization process for flowering plants is particularly complex ... female reproductive cells. New research from an international ... including Carnegie,s Wolf Frommer, David Ehrhardt, and Guido ... that guides flowering plant fertilization. It is published ...
Breaking Biology News(10 mins):Hormone analysis helps identify horny rhinos 2Calcium and reproduction go together 2
... ESA,s Envisat satellite, shows the vast cloud of volcanic ash ... than 1000 km away. Carried by winds high up ... of the Eyjafjallajoekull glacier in southwest Iceland has led to ... further disruption in northern Europe expected later today. The ash, ...
... This press release is available in French . ... of the 20th century, but new research shows initiatives of ... dollars as people might think. McGill University Biologist Dr. Jonathan ... most affected by them is a far more effective and ...
... BioTorrents: A File Sharing Service Abstract:, The ... challenge, as datasets continue to grow in size and ... file transfer do not scale well for large files ... we present BioTorrents, a website that allows open access ...
Cached Biology News:Trying to eradicate a disease is a waste of money: researcher 2BioTorrents: An OA file sharing service and more 2BioTorrents: An OA file sharing service and more 3BioTorrents: An OA file sharing service and more 4BioTorrents: An OA file sharing service and more 5
... Using multicolor analysis in a modern flow ... cells that are differentially labeled with fluorescent ... dyes typically used for cell labeling are ... by a flow cytometers filters. Thus, the ...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... leading provider of X-ray crystallography services ... screening services to its pharmaceutical and ... binding of drug-like fragments to the ... targets, allowing scientists to develop novel, ...
...
Biology Products: